Dr. Michael H. Bar, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 285
Licensed in Connecticut since 1990, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CT license 030565 (first issued 1990; active) -
Hematology (Internal Medicine) Physician
CT license 030565 (first issued 1990; active) -
Medical Oncology Physician
CT license 030565 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 285
- Services billed
- 806
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 467 | 197 |
| Established patient office or other outpatient visit, 40-54 minutes | 184 | 90 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 66 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 61 | 34 |
| New patient office or other outpatient visit, 60-74 minutes | 48 | 48 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 36 | 34 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imbruvica (ibrutinib) | 63 |
| Venclexta (venetoclax) | 62 |
| Hydroxyurea Other prescribers in Stamford, CT | 55 |
| Brukinsa (zanubrutinib) | 25 |
| Promacta (eltrombopag olamine) | 18 |
| Xarelto (rivaroxaban) Other prescribers in Stamford, CT | 12 |
| Deferiprone | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $20.65 in total to this clinician.
| GlaxoSmithKline, LLC. | $20.65 |
|---|
| Food and Beverage | $20.65 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $13,175 in research payments for these studies, mostly to the institutions running them.
- Connect® MM- The Multiple Myeloma Disease Registry
E.r. Squibb & Sons, L.l.c. · Terminated · NCT01081028 - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.